Completed

NCT Number: NCT05330130

Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells

To study the influence of different daily rec-FSH dosages (150 IU versus 300 IU), performed in the same patient in consecutive cycles, on the relation between FSH- and LH-receptors of the granulosa cells of the growing follicle.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ovarian Function Insufficiency Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Fertility Issues Genital Diseases Genital Diseases, Female Infertility Infertility, Female Infertility,Female Urogenital Diseases

Age range

18 year–38 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

ART Fertility Clinics LLC

Abu Dhabi, 60202, United Arab Emirates

About this study

This is a prospective cross-over study. Investigators want to study the effect of different dosages of recombinant FSH in the same patient on the expression of the FSH- and LH-receptors in the granulosa cells and on the endocrine milieu in the blood and the follicular fluid. An improved understanding of the mechanism leading to progesterone elevation might initiate a change in the ovarian stimulation approach, thereby not only preventing progesterone elevation and its negative consequences on ART (Assisted Reproductive Technology) outcome, but also improving individualization of the ovarian stimulation treatment according to the patients' characteristics.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Desire to perform oocyte freezing for social fertility preservation, age 18 - 38 years
BMI of 18-32 kg/m2
Regular menstrual cycles with a length of 24-35 days
Anti-Muellerian-Hormone levels between 1.3 - 6.25 ng/ml (Ferraretti and Gianaroli, 2014; Calzada et al., 2019)

Exclusion criteria

Occurrence of ovarian hyperstimulation syndrome (OHSS)
Occurrence of poor ovarian response (AFC < 5 and AMH < 0,5ng/ml) in previous ovarian stimulation treatment (20)
Polycystic ovary syndrome (PCOS) (21)

Treatment and study plan

Follitropin beta injection 150 IU

Drug

Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:

one follicle on the morning of day 5, before the administration of the first GnRH-antagonist
one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm
two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.

Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.

Other names: FOLLISTIM AQ

Follitropin beta injection 300 IU

Drug

Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:

one follicle on the morning of day 5, before the administration of the first GnRH-antagonist
one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm
two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.

Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.

Other names: FOLLISTIM AQ

Primary outcomes

Number of FSHR- and LHR of the GC, obtained from one follicle on the morning of day 5, before the administration of the first GnRH-antagonist, punctured during the ovarian stimulation cycle

Time frame: 5 days
Number of FSHR- and LHR of the GC, obtained from tone follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm, punctured during the ovarian stimulation cycle

Time frame: 1 day
Number of FSHR- and LHR of the GC, obtained from two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation, punctured during the ovarian stimulation cycle

Time frame: 1 day
Number of FSHR- and LHR of the GC, obtained from the follicular fluid of follicles aspirated during OPU

Time frame: 1 day

Secondary outcomes

Level of E2 hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist

Time frame: 5 days
Level of P4 hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist

Time frame: 5 days
Level of FSH hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist

Time frame: 5 days
Level of LH hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist

Time frame: 5 days
Level of E2 hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm

Time frame: 1 day
Level of P4 hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm

Time frame: 1 day
Level of FSH hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm

Time frame: 1 day
Level of LH hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm

Time frame: 1 day
Level of E2 hormone in the blood, on the morning of the day of final oocyte maturation

Time frame: 1 day
Level of P4 hormone in the blood, on the morning of the day of final oocyte maturation

Time frame: 1 day
Level of FSH hormone in the blood, on the morning of the day of final oocyte maturation

Time frame: 1 day
Level of LH hormone in the blood, on the morning of the day of final oocyte maturation

Time frame: 1 day
Level of E2 hormone in the blood, on the day of OPU

Time frame: 1 day
Level of P4 hormone in the blood, on the day of OPU

Time frame: 1 day
Level of FSH hormone in the blood, on the day of OPU

Time frame: 1 day
Level of LH hormone in the blood, on the day of OPU

Time frame: 1 day
Level of E2 hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist

Time frame: 5 days
Level of P4 hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist

Time frame: 5 days
Level of FSH hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist

Time frame: 5 days
Level of LH hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist

Time frame: 5 days
Level of E2 hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm

Time frame: 1 day
Level of P4 hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm

Time frame: 1 day
Level of FSH hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm

Time frame: 1 day
Level of LH hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm

Time frame: 1 day
Level of E2 hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation

Time frame: 1 day
Level of P4 hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation

Time frame: 1 day
Level of FSH hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation

Time frame: 1 day
Level of LH hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation

Time frame: 1 day
Level of E2 hormone in the follicular fluid of follicles aspirated during OPU

Time frame: 1 day
Level of P4 hormone in the follicular fluid of follicles aspirated during OPU

Time frame: 1 day
Level of FSH hormone in the follicular fluid of follicles aspirated during OPU

Time frame: 1 day
Level of LH hormone in the follicular fluid of follicles aspirated during OPU

Time frame: 1 day

Sponsors and collaborators

Lead sponsor

ART Fertility Clinics LLC

Other

Collaborators

Organon and Co

Registry information

Official study title

Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI on the Expression of FSH- and LH-receptors in Granulosa Cells

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Apr 15, 2022
Registry last updated: Jan 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed

Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?

NCT05489367

COVID-19, COVID-19 Virus Infection

Istanbul, Gaziosmanpaşa, Turkey (Türkiye)

View Trial Details

Completed

GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients

NCT00429494

Adnexal Diseases, Amenorrhea

Houston, Texas, United States

View Trial Details

Completed

Attention to Variability During Infertility

NCT03712982

Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications

Waltham, Massachusetts, United States

View Trial Details

Completed

Effect of Vitrification and Warming Media on Pregnancy Rates in the Context of Oocyte Donation

NCT07288866

Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications

Clermont-Ferrand, Auvergne, France

View Trial Details

Key information

Conditions

Age range

Sex eligibility

Study type

Phase

Primary location

ART Fertility Clinics LLC

About this study

Who can participate

Treatment and study plan

Follitropin beta injection 150 IU

Follitropin beta injection 300 IU

Primary outcomes

Number of FSHR- and LHR of the GC, obtained from one follicle on the morning of day 5, before the administration of the first GnRH-antagonist, punctured during the ovarian stimulation cycle

Number of FSHR- and LHR of the GC, obtained from tone follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm, punctured during the ovarian stimulation cycle

Number of FSHR- and LHR of the GC, obtained from two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation, punctured during the ovarian stimulation cycle

Number of FSHR- and LHR of the GC, obtained from the follicular fluid of follicles aspirated during OPU

Secondary outcomes

Level of E2 hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist

Level of P4 hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist

Level of FSH hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist

Level of LH hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist

Level of E2 hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm

Level of P4 hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm

Level of FSH hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm

Level of LH hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm

Level of E2 hormone in the blood, on the morning of the day of final oocyte maturation

Level of P4 hormone in the blood, on the morning of the day of final oocyte maturation

Level of FSH hormone in the blood, on the morning of the day of final oocyte maturation

Level of LH hormone in the blood, on the morning of the day of final oocyte maturation

Level of E2 hormone in the blood, on the day of OPU

Level of P4 hormone in the blood, on the day of OPU

Level of FSH hormone in the blood, on the day of OPU

Level of LH hormone in the blood, on the day of OPU

Level of E2 hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist

Level of P4 hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist

Level of FSH hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist

Level of LH hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist

Level of E2 hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm

Level of P4 hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm

Level of FSH hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm

Level of LH hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm

Level of E2 hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation

Level of P4 hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation

Level of FSH hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation

Level of LH hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation

Level of E2 hormone in the follicular fluid of follicles aspirated during OPU

Level of P4 hormone in the follicular fluid of follicles aspirated during OPU

Level of FSH hormone in the follicular fluid of follicles aspirated during OPU

Level of LH hormone in the follicular fluid of follicles aspirated during OPU

Sponsors and collaborators

Lead sponsor

Collaborators

Registry information

Official study title

Important dates

Related clinical trials

Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?

GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients

Attention to Variability During Infertility

Effect of Vitrification and Warming Media on Pregnancy Rates in the Context of Oocyte Donation